Cantor Fitzgerald initiated coverage on Summit Therapeutics
$SMMT
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $23.00 → $35.00 | Neutral → Buy | Citigroup |
| 3/21/2025 | Overweight | Cantor Fitzgerald | |
| 3/12/2025 | $30.00 | Outperform | Evercore ISI |
| 2/28/2025 | $42.00 | Buy | Goldman |
| 1/8/2025 | $35.00 | Buy | Truist |
| 12/11/2024 | $30.00 | Overweight | Wells Fargo |
| 12/6/2024 | $31.00 | Buy | Jefferies |
| 11/4/2024 | $32.00 | Mkt Outperform | JMP Securities |
10-Q - Summit Therapeutics Inc. (0001599298) (Filer)
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
DEF 14A - Summit Therapeutics Inc. (0001599298) (Filer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic
Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and
Clinical Trial Collaboration with Pfizer Evaluating Ivonescimab in Combination with Several Vedotin ADCs in Unique Solid Tumor Settings; Clinical Trials Expected to Start Mid-2025 Enrollment Completed for Global, Multi-Regional Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Top-Line Data Expected Mid-2025; Received Fast Track Designation from FDA HARMONi-3 Global Phase III Trial Expanded to Include Patients with Squamous and Non-Squamous Histologies Initial Trial Sites Activated for Global Phase III HARMONi-7 Trial in 1L PD-L1 High, Advanced NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an updat
SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)
SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)
SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)
Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic
Interim Analysis of HARMONi-2 Shows an Overall Survival Hazard Ratio of 0.777 Favoring Ivonescimab at 39% Data Maturity, Implying a Potential Numerical 22% Reduction in the Risk of Death Compared to Pembrolizumab Ivonescimab Monotherapy Approved by NMPA in China for Front-Line PD-L1 Positive Advanced NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monother
Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
4 - Summit Therapeutics Inc. (0001599298) (Issuer)
Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously
Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight
Evercore ISI initiated coverage of Summit Therapeutics with a rating of Outperform and set a new price target of $30.00